23.5 C
New York
Thursday, July 3, 2025

Tag: infections

newssourcecompanyFORcontentinformation1marketbusiness

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer 

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID...

Invivyd Forms SPEAR (Spike Protein Elimination and Recovery) Study Group with Researches to Assess Effects of Monoclonal Antibody Therapy for Long COVID

Strobilurin Market worth $6.88 billion by 2030- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 2, 2025 /PRNewswire/ -- The strobilurin market is projected to expand from USD 5.53 billion in 2025 to USD 6.88...

Strobilurin Market worth $6.88 billion by 2030- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 2, 2025 /PRNewswire/ -- The strobilurin market is projected to expand from USD 5.53 billion in 2025 to USD 6.88...

Everest Medicines Announces Updated Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of...

As of March 21st, 2025, longer follow-up data was collected from the ongoing Ph1b/2a study of EVER001: in Cohort 1, 11 patients completed 52...

BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate

Ad hoc announcement pursuant to Art. 53 LR

NADPH Oxidase (NOX)-Replacement Therapies Market to Observe Stunning Growth During the Forecast Period (2025-2034) Across 7MM | DelveInsight

The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....

NADPH Oxidase (NOX)-Replacement Therapies Market to Observe Stunning Growth During the Forecast Period (2025-2034) Across 7MM | DelveInsight

The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage development and gain regulatory approval....

Pet King Brands’ ZYMOX® Designated as a 2025 Vanguard Awards Winner in Eye and Ear Care

Pet Insight Magazine recognizes ZYMOX as a category trailblazer. AUSTIN, Texas, June 30, 2025 /PRNewswire/ -- Pet King Brands, a pioneering leader in veterinarian-recommended enzymatic...

Finding Suggests Treatment Approach for Autoimmune Diseases

NEW YORK, June 30, 2025 /PRNewswire/ -- An engineered protein turns off the kind of immune cells most likely to damage tissue as part...

Challenge accepted: New funding for ambitious projects within biomanufacturing, cardiometabolic diseases, and artificial intelligence

The 2025 Novo Nordisk Foundation Challenge Programme awards DKK 479 million to nine innovative projects that advance health and sustainability through cooperation between researchers from...

Challenge accepted: New funding for ambitious projects within biomanufacturing, cardiometabolic diseases, and artificial intelligence

The 2025 Novo Nordisk Foundation Challenge Programme awards DKK 479 million to nine innovative projects that advance health and sustainability through cooperation between researchers from...

Landmark Study Affirms MolecuLight’s Efficacy in Real-Time Bacterial Detection for Improved Wound Management

TORONTO, June 26, 2025 /PRNewswire/ -- MolecuLight Inc., a global pioneer in point-of-care fluorescence imaging for wound care, proudly announces the publication of a...

Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results

LIKMEZ™ (ATI-1501) for Metronidazole Oral Suspension 500mg/5mL re-launched and commercial sales ongoing  

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInfections

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers